SURGERY PARTNERS INC (SGRY) Fundamental Analysis & Valuation
NASDAQ:SGRY • US86881A1007
Current stock price
14.27 USD
+0.24 (+1.71%)
At close:
14.1 USD
-0.17 (-1.19%)
After Hours:
This SGRY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SGRY Profitability Analysis
1.1 Basic Checks
- In the past year SGRY was profitable.
- SGRY had a positive operating cash flow in the past year.
- SGRY had negative earnings in each of the past 5 years.
- Each year in the past 5 years SGRY had a positive operating cash flow.
1.2 Ratios
- SGRY has a Return On Assets (-0.96%) which is in line with its industry peers.
- SGRY has a Return On Equity (-4.55%) which is in line with its industry peers.
- SGRY's Return On Invested Capital of 5.05% is in line compared to the rest of the industry. SGRY outperforms 58.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for SGRY is below the industry average of 8.40%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.96% | ||
| ROE | -4.55% | ||
| ROIC | 5.05% |
ROA(3y)-1.09%
ROA(5y)-1.08%
ROE(3y)-4.85%
ROE(5y)-4.95%
ROIC(3y)5.12%
ROIC(5y)4.89%
1.3 Margins
- SGRY has a Operating Margin of 14.49%. This is amongst the best in the industry. SGRY outperforms 89.00% of its industry peers.
- In the last couple of years the Operating Margin of SGRY has grown nicely.
- SGRY has a Gross Margin of 25.78%. This is comparable to the rest of the industry: SGRY outperforms 55.00% of its industry peers.
- SGRY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.49% | ||
| PM (TTM) | N/A | ||
| GM | 25.78% |
OM growth 3Y-0.58%
OM growth 5Y7.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y0.52%
2. SGRY Health Analysis
2.1 Basic Checks
- SGRY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for SGRY has been increased compared to 1 year ago.
- SGRY has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, SGRY has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.71, we must say that SGRY is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 0.71, SGRY is doing worse than 71.00% of the companies in the same industry.
- SGRY has a debt to FCF ratio of 18.93. This is a negative value and a sign of low solvency as SGRY would need 18.93 years to pay back of all of its debts.
- SGRY has a Debt to FCF ratio of 18.93. This is in the lower half of the industry: SGRY underperforms 65.00% of its industry peers.
- A Debt/Equity ratio of 2.10 is on the high side and indicates that SGRY has dependencies on debt financing.
- With a Debt to Equity ratio value of 2.10, SGRY is not doing good in the industry: 74.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.1 | ||
| Debt/FCF | 18.93 | ||
| Altman-Z | 0.71 |
ROIC/WACC0.55
WACC9.2%
2.3 Liquidity
- SGRY has a Current Ratio of 1.87. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
- SGRY has a Current ratio of 1.87. This is in the better half of the industry: SGRY outperforms 78.00% of its industry peers.
- A Quick Ratio of 1.71 indicates that SGRY should not have too much problems paying its short term obligations.
- SGRY has a better Quick ratio (1.71) than 74.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.87 | ||
| Quick Ratio | 1.71 |
3. SGRY Growth Analysis
3.1 Past
- SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.06%.
- Measured over the past years, SGRY shows a very strong growth in Earnings Per Share. The EPS has been growing by 52.38% on average per year.
- The Revenue has been growing slightly by 6.24% in the past year.
- The Revenue has been growing by 12.21% on average over the past years. This is quite good.
EPS 1Y (TTM)-51.06%
EPS 3Y52.38%
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)6.24%
Revenue growth 3Y9.22%
Revenue growth 5Y12.21%
Sales Q2Q%2.38%
3.2 Future
- The Earnings Per Share is expected to grow by 17.17% on average over the next years. This is quite good.
- SGRY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.28% yearly.
EPS Next Y-46.78%
EPS Next 2Y-0.67%
EPS Next 3Y12.18%
EPS Next 5Y17.17%
Revenue Next Year3.61%
Revenue Next 2Y4.63%
Revenue Next 3Y5.91%
Revenue Next 5Y8.28%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. SGRY Valuation Analysis
4.1 Price/Earnings Ratio
- SGRY is valuated quite expensively with a Price/Earnings ratio of 31.02.
- SGRY's Price/Earnings is on the same level as the industry average.
- When comparing the Price/Earnings ratio of SGRY to the average of the S&P500 Index (26.64), we can say SGRY is valued inline with the index average.
- A Price/Forward Earnings ratio of 58.29 indicates a quite expensive valuation of SGRY.
- SGRY's Price/Forward Earnings ratio is in line with the industry average.
- SGRY's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.02 | ||
| Fwd PE | 58.29 |
4.2 Price Multiples
- SGRY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SGRY is cheaper than 81.00% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, SGRY is valued cheaper than 84.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.44 | ||
| EV/EBITDA | 8.05 |
4.3 Compensation for Growth
- SGRY's earnings are expected to grow with 12.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.67%
EPS Next 3Y12.18%
5. SGRY Dividend Analysis
5.1 Amount
- No dividends for SGRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SGRY Fundamentals: All Metrics, Ratios and Statistics
14.27
+0.24 (+1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Industry Strength60.87
Industry Growth63.98
Earnings (Last)03-02 2026-03-02/amc
Earnings (Next)05-05 2026-05-05/bmo
Inst Owners83.54%
Inst Owner Change-0.32%
Ins Owners1.63%
Ins Owner Change1.19%
Market Cap1.85B
Revenue(TTM)3.31B
Net Income(TTM)-77.90M
Analysts81.11
Price Target19.66 (37.77%)
Short Float %20.58%
Short Ratio10.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.91%
Min EPS beat(2)-60.78%
Max EPS beat(2)-23.03%
EPS beat(4)1
Avg EPS beat(4)-21%
Min EPS beat(4)-60.78%
Max EPS beat(4)24.15%
EPS beat(8)4
Avg EPS beat(8)-6.88%
EPS beat(12)8
Avg EPS beat(12)176.88%
EPS beat(16)9
Avg EPS beat(16)102.65%
Revenue beat(2)1
Avg Revenue beat(2)-0.88%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)0.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)0.14%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)4
Avg Revenue beat(12)-0.76%
Revenue beat(16)6
Avg Revenue beat(16)-0.79%
PT rev (1m)-24.28%
PT rev (3m)-25.87%
EPS NQ rev (1m)2.69%
EPS NQ rev (3m)-519.28%
EPS NY rev (1m)-67.35%
EPS NY rev (3m)-67.35%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)-2.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.02 | ||
| Fwd PE | 58.29 | ||
| P/S | 0.56 | ||
| P/FCF | 9.44 | ||
| P/OCF | 6.73 | ||
| P/B | 1.08 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.05 |
EPS(TTM)0.46
EY3.22%
EPS(NY)0.24
Fwd EY1.72%
FCF(TTM)1.51
FCFY10.59%
OCF(TTM)2.12
OCFY14.85%
SpS25.57
BVpS13.24
TBVpS-27.22
PEG (NY)N/A
PEG (5Y)N/A
Graham Number11.704 (-17.98%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.96% | ||
| ROE | -4.55% | ||
| ROCE | 6.39% | ||
| ROIC | 5.05% | ||
| ROICexc | 5.21% | ||
| ROICexgc | 18.67% | ||
| OM | 14.49% | ||
| PM (TTM) | N/A | ||
| GM | 25.78% | ||
| FCFM | 5.91% |
ROA(3y)-1.09%
ROA(5y)-1.08%
ROE(3y)-4.85%
ROE(5y)-4.95%
ROIC(3y)5.12%
ROIC(5y)4.89%
ROICexc(3y)5.3%
ROICexc(5y)5.11%
ROICexgc(3y)19.01%
ROICexgc(5y)18.72%
ROCE(3y)6.48%
ROCE(5y)6.19%
ROICexgc growth 3Y2.9%
ROICexgc growth 5Y5.08%
ROICexc growth 3Y1.35%
ROICexc growth 5Y9.67%
OM growth 3Y-0.58%
OM growth 5Y7.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y0.52%
F-Score5
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.1 | ||
| Debt/FCF | 18.93 | ||
| Debt/EBITDA | 5.5 | ||
| Cap/Depr | 44.72% | ||
| Cap/Sales | 2.38% | ||
| Interest Coverage | 1.87 | ||
| Cash Conversion | 41.85% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.87 | ||
| Quick Ratio | 1.71 | ||
| Altman-Z | 0.71 |
F-Score5
WACC9.2%
ROIC/WACC0.55
Cap/Depr(3y)59.72%
Cap/Depr(5y)61.53%
Cap/Sales(3y)2.84%
Cap/Sales(5y)2.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.06%
EPS 3Y52.38%
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y-46.78%
EPS Next 2Y-0.67%
EPS Next 3Y12.18%
EPS Next 5Y17.17%
Revenue 1Y (TTM)6.24%
Revenue growth 3Y9.22%
Revenue growth 5Y12.21%
Sales Q2Q%2.38%
Revenue Next Year3.61%
Revenue Next 2Y4.63%
Revenue Next 3Y5.91%
Revenue Next 5Y8.28%
EBIT growth 1Y1.03%
EBIT growth 3Y8.59%
EBIT growth 5Y20.49%
EBIT Next Year28.56%
EBIT Next 3Y15.28%
EBIT Next 5YN/A
FCF growth 1Y-6.72%
FCF growth 3Y35.74%
FCF growth 5Y-0.84%
OCF growth 1Y-8.6%
OCF growth 3Y19.98%
OCF growth 5Y2.13%
SURGERY PARTNERS INC / SGRY Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 3 / 10 to SGRY.
What is the valuation status for SGRY stock?
ChartMill assigns a valuation rating of 4 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.
Can you provide the profitability details for SURGERY PARTNERS INC?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
What is the valuation of SURGERY PARTNERS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SURGERY PARTNERS INC (SGRY) is 31.02 and the Price/Book (PB) ratio is 1.08.
Can you provide the expected EPS growth for SGRY stock?
The Earnings per Share (EPS) of SURGERY PARTNERS INC (SGRY) is expected to decline by -46.78% in the next year.